2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details

臨床試験数 : 645 /  薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04654689
(ClinicalTrials.gov)		November 20, 202113/11/2020Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS PatientsImpact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With G04CB02 on the Clinical Improvement of ALS PatientsAmyotrophic Lateral SclerosisDietary Supplement: Liposomed polyphenols resveratrol and curcumin;Other: Placebo for liposomed resveratrol and curcumin;Dietary Supplement: Isocaloric Diet;Drug: G04CB02;Other: Placebo microcrystalline methylcelluloseFundación Universidad Católica de Valencia San Vicente MártirNULLActive, not recruiting18 Years75 YearsAll90Phase 2Spain
2EUCTR2021-001989-38-ES
(EUCTR)		08/07/202114/06/2021COMPARISON OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE IMPROVEMENT OF PATIENTS WITH ELA WHO ARE BEING TREATED WITH RILUZOLEIMPACT OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE CLINICAL IMPROVEMENT OF PATIENTS WITH ALS TREATED WITH RILUZOLE - IMCRELA Amyotrophic Lateral Sclerosis
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Dutasterida
Product Name: Dutasterida
INN or Proposed INN: DUTASTERIDE
Other descriptive name: DUTASTERIDE		Facultad de medicina y ciencias de la salud de la Universidad Católica de ValenciaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		100Phase 2Spain